Sightera Biosciences Secures $3 Million in Latest Pre-Seed Funding Round

Sightera Biosciences secured $3 million in its latest Pre-Seed, adding another data point to the Healthcare & Life Sciences funding market.

Sightera Biosciences Raises $3 million in Funding

Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform - Tech.eu Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform. Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first — TFN sightera biosciences. Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform.

Investors Behind the Funding

The round was backed by 'extreme' patient biology first — TFN sightera biosciences. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Sightera Biosciences operates in Healthcare & Life Sciences. Sightera Biosciences's financing adds to recent private-market activity.

Strategic Use of Funds

Expand its patient-derived AI drug discovery platform.

Looking Ahead

Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform

Source reference: original announcement/article.